Nanovibronix, Inc. (NASDAQ:FEED – Get Free Report)’s share price traded down 24.3% during trading on Friday. The stock traded as low as $0.3711 and last traded at $0.3711. 2,794 shares traded hands during trading, a decline of 99% from the average daily volume of 377,047 shares. The stock had previously closed at $0.49.
Analyst Ratings Changes
A number of analysts recently weighed in on FEED shares. Wall Street Zen raised shares of Nanovibronix from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Nanovibronix in a research note on Tuesday, July 21st. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
Check Out Our Latest Report on Nanovibronix
Nanovibronix Stock Performance
The firm has a market capitalization of $342,896.40, a P/E ratio of -0.00 and a beta of 1.46. The business has a fifty day moving average of $2.55 and a 200-day moving average of $8.28.
About Nanovibronix
NanoVibronix is a medical device company that develops and markets therapeutic products based on its proprietary low-intensity, long-duration ultrasound technology. Its devices are designed to support pain management, wound care and other clinical applications.
The company’s product portfolio has included PainShield, a wearable ultrasound device intended to provide localized pain relief; WoundShield, which is designed to support wound treatment; and UroShield, a device developed for managing discomfort associated with urinary catheterization.
Further Reading
- Five stocks we like better than Nanovibronix
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
